Bayer's Two Clinical Wins Land, but the Street Can't Agree on What They're Worth
Published on 10/27/2026 at 14:11 | Editorial boerse-global.de
Bayer shares drew support from a pair of pharmaceutical announcements on Tuesday, though the market's reaction and the analyst community's response tell two rather different stories about how much those wins are actually worth.
The stock finished the session at EUR 45.65, a gain of 3.9%. Behind the move: a closely watched interim result for Nubeqa in high-risk prostate cancer, and a regulatory green light in China for the stroke-prevention drug Asundexian.
A 58% Risk Reduction — in a Precisely Defined Setting
Bayer reported that Nubeqa (darolutamide) cut the risk of metastases or death by 58% in a pre-planned interim analysis of the Phase III DASL-HiCaP trial. The finding rests on a median follow-up of 3.8 years and applies to the trial's combined endpoint of metastasis or death.
The comparison matters as much as the headline number. Nubeqa was given alongside androgen deprivation therapy and radiotherapy, with the control arm receiving placebo plus the same ADT and radiation backbone. The 58% figure describes that specific head-to-head comparison — not a revenue forecast, and not a statement about Bayer's future earnings.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer also disclosed absolute figures for a fixed time point: the four-year metastasis-free survival rate came in at 95% in the Nubeqa arm versus 88% for the comparator group.
China Clears Sunharbo
Separately, China's NMPA approved Asundexian under the brand name Sunharbo for reducing the risk of stroke in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Bayer described the compound as the world's first approved FXIa inhibitor.
The two announcements carry different regulatory weight. Asundexian's is a completed approval decision in a defined indication; Nubeqa's is an interim clinical readout that supports the drug's outlook in an additional treatment setting.
JPMorgan Sticks With Overweight, Jefferies Stays on Hold
Analysts were quick to weigh in, and their verdicts diverged sharply. JPMorgan reaffirmed its Overweight rating with a EUR 61 price target, according to media reports, with Richard Vosser taking a positive view of the DASL-HiCaP interim data.
Jefferies, by contrast, maintained its Hold rating and a EUR 46 target following the darolutamide results, also per media reports. The gap between the two targets — EUR 15 — illustrates how the same clinical news release can support very different investment conclusions.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Real Test Arrives November 3
What neither the data nor the ratings can settle is the question investors keep circling back to: how convincingly can Bayer translate medical progress into commercial results?
The company's third-quarter 2026 figures, scheduled for release on November 3, 2026, will be the next concrete checkpoint. Until then, the bull case rests on linking pipeline momentum to a credible business outlook. If management can draw a clear line from product development to financial perspective, confidence in a re-rating has a firmer footing. If that connection looks weak, caution remains defensible even without any doubt about the science itself.
Ad
Bayer Stock: New Analysis - 27 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
